mcw casino live score PIERS Morgan has lead well-wishes for Michail Antonio after a car crash saw him trapped in his Ferrari for 45 minutes. The footballer, 34, was airlifted to hospital with "shattered" legs after the horror unfolded on Coppice Row, in Epping, Essex, at around 12.50pm. 5 Piers Morgan has led well-wishes after the horror crash Credit: Rex 5 A source told The Sun on Sunday 'everyone at the club is very worried' Credit: Getty 5 Photographs at the scene show extensive damage to the front of the Ferrari Credit: X 5 The footballer was trapped for nearly an hour before fire crews cut him free Credit: X Michail was eventually cut free by fire crews at 1.45pm after being trapped for nearly an hour. Piers Morgan posted his well-wishes on X after shocking photographs from the scene circulated. "Whoa... this looks very bad. Hope he’s OK," wrote the Uncensored host. When West Ham later posted a major health update stating the player was in "stable condition", the presenter added: "Good news...". Read More HORROR SMASH Michail Antonio trapped in Ferrari for almost an HOUR before being airlifted Michail's former team-mate Jobi McAnuff, who played with him at Reading, also wrote on Instagram: "Thoughts and prayers to Michail and his family." It comes after the footballer's £260,000 Ferrari FF smashed into trees after leaving the road. Ex-wife Debbie travelled from her home in Manchester to be at his bedside. A source told The Sun on Sunday: “He is in a serious condition. Most read in Football GER WARNED Philippe Clement issues warning to glory hunters ahead of Ross County clash NOT HAPPY Celtic boss Brendan Rodgers reveals how his starts left him 'concerned' v Hibs CELTIC 3 HIBS 0 Gray rues missed chances as MOTM Schmeichel racks up ANOTHER clean sheet HEALTH UPDATE West Ham issues major update after star involved in horror crash “He is conscious and communicating but everyone at the club is very worried. We are all just praying he gets through this.” Onlookers reported grey smoke pouring from the car which crashed in Theydon Bois — close to the home of West Ham owner David Sullivan. One said: “There were other cars stopped and people were on their phones calling 999. “It was awful weather, rain, wind and very slippery on the road. It didn’t look like another car was involved. "It looked like it had spun out of control. “I only found out later who he was. I hope he’s OK.” A motorist who passed the scene added: “The right wing was ripped off, as well as the right front wheel and driver’s door. “I could see firefighters had to cut away parts of the car to get him out. It looked like he had some face injuries.” Another source also claimed the footballer's legs had been "shattered" in the crash. Horrific photographs from the scene show the shocking aftermath. Michail's silver Ferrari lay at the side of the road on the verge of surrounding woodland. There appeared to be extensive damage to the front, driver's side, with the windshield crumpled. Pictures revealed only the back of the car remained in tact. In an update on X, the club confirmed Michail is in a "stable condition" and remains in hospital after the single vehicle collision. The dad-of-four is "under close supervision" but is "conscious and communicating". "West Ham United can confirm that Michail Antonio is in a stable condition following a road traffic accident this afternoon in the Essex area," the club wrote on social media. "Michail is conscious and communicating and is currently under close supervision at a central London hospital. "At this difficult time, we kindly ask everyone to respect the privacy of Michail and his family. "The Club will make no further comment this evening, but will issue a further update in due course." Fans on X were quick to send their best wishes and prayers following the latest update. One said: "Amazing news. Here’s to speedy recovery Michail take all the time you need." Another added: "Good news! Glad to hear this." A third said: "Wishing Michail Antonio a speedy recovery. Glad to hear he's in stable condition. "Thoughts are with him and his family during this difficult time. Hoping for a full and quick recovery." A spokesperson for Essex Police said: "Officers investigating a serious collision in Epping are asking for witnesses and dash cam footage. "We were called shortly after 12.50pm on Saturday 7 December to Coppice Row, Epping, following reports of what is believed to be a single vehicle collision involving a Ferrari. "Emergency services attended and the driver has been taken to hospital. "The vehicle has been recovered and we are no longer on scene. "An investigation will be carried out by our Roads Policing Unit. "If you have any information, CCTV, dash cam or other footage in relation to this incident, then please get in contact with us. "Please quote incident 605 of 7 December when providing any information to make sure it gets to the right person as quickly as possible. "Alternatively, please email the investigating officer, PS Mark Hewitt." An Essex Fire and Rescue Service spokesperson added: "Crews were called to High Road, Epping, at 1.02pm this afternoon after reports of a road traffic collision involving one car. Read more on the Scottish Sun FERRY WINDY Ferry stranded amid Storm Darragh as passengers stuck on ship for 12 hours HORROR BLAZE Huge fire erupts at Scots industrial estate as emergency crews race to scene "On arrival firefighters reported that a man was trapped in his car and worked to release him by 1.45pm. "The casualty was left in the care of the Ambulance Service." 5 The player is in 'stable condition' Credit: Getty

McNeese topples Illinois State basketballBlood disorders affect millions worldwide—an estimated 5% of the global population suffers from conditions like anemia, and others. Anemia is a silent epidemic, with over 2 billion people affected globally, often caused by iron deficiency or chronic diseases. With ongoing research, the treatment landscape for blood disorders continues to evolve, from targeted therapies to life-saving gene editing technologies. LAS VEGAS , Dec. 9, 2024 /PRNewswire/ -- Blood disorders are a group of conditions that affect the production, function, or structure of blood cells, leading to various health complications. These disorders can involve issues with red blood cells, white blood cells, platelets, or the plasma components of blood. Common types of blood disorders include anemia, where there is a deficiency of red blood cells or hemoglobin, leading to fatigue and weakness, and thrombocytopenia, characterized by low platelet counts, which can cause excessive bleeding. The causes of blood disorders range from genetic factors and autoimmune conditions to infections and environmental factors. Treatment options depend on the specific disorder and may include medications, blood transfusions, or bone marrow transplants. DelveInsight has recently released a series of epidemiology-based market reports focusing on blood disorders including Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia . These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034 segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Additionally, the reports feature an examination of prominent companies working with their lead candidates in different stages of clinical development. Let's deep dive into the assessment of these blood disorders markets individually. Immune Thrombocytopenia Market Immune thrombocytopenic purpura (ITP) is an autoimmune condition marked by a low platelet count, resulting in bruising and bleeding. It manifests as acute in children and chronic in adults. The primary treatments are corticosteroids, intravenous immunoglobulin (IVIg), and rituximab. In the 7MM, the United States reported the highest prevalence of ITP, with nearly 66,500 cases in 2023. Primary ITP, which accounts for 80% of cases, occurs without any underlying diseases, while secondary ITP, making up about 20% of cases, is linked to conditions such as systemic lupus erythematosus (SLE), medications, infections, and other autoimmune diseases. In immune thrombocytopenia, the initial treatment generally consists of corticosteroids, with prednisone prescribed at 1 mg/kg/day for 21-28 days, followed by a gradual taper. High-dose dexamethasone (40 mg/day for 4 days) may lead to a more pronounced platelet response. Intravenous immunoglobulin (IVIG) or intravenous anti-D (Rho[D] immune globulin) may be used as first-line options, particularly in urgent situations requiring quick platelet increases. However, many adults experience relapses or do not respond to first-line therapy, necessitating second-line treatments. IVIG is effective in 70-80% of cases, and anti-D works in 50-70% of RhD-positive patients. Splenectomy is a well-established second-line option, though it carries risks such as infection and bleeding. Rituximab , a monoclonal antibody that targets CD20, has shown strong efficacy both before and after splenectomy. Thrombopoietin-receptor agonists, such as romiplostim and eltrombopag, are also effective second-line treatments as they promote platelet production by activating the thrombopoietin receptor. In the US, the approved treatments for ITP are DOPTELET, TAVALISSE, PROMACTA, and NPLATE . The EU market for thrombocytopenia is primarily driven by both approved and off-label therapies. In the EU, approved treatments include DOPTELET (avatrombopag), TAVALISSE/TAVLESSE (fostamatinib), PROMACTA/REVOLADE (eltrombopag), and NPLATE/Romiplate (romiplostim) . RITUXAN is only approved in Japan for the treatment of ITP. Learn more about the FDA-approved drugs for ITP @ Drugs for Immune Thrombocytopenic Purpura Treatment As per DelveInsight analysis, in 2023, the total ITP market size in the 7MM was USD 3.1 billion . As per the estimates, PROMACTA (eltrombopag) achieved the highest revenue among all medications in the 7MM in 2023. The market is expected to show positive growth, mainly attributed to the increasing cases and also, the launch of upcoming therapies during the forecast period (2024–2034). Immune Thrombocytopenic Purpura Pipeline Therapies and Key Companies Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma Mezagitamab (TAK-079): Millennium Pharmaceuticals/Takeda Efgartigimod (ARGX-113): argenx BT-595: Biotest Dive deeper for rich insights into the Immune Thrombocytopenic Purpura Clinical Trials Aplastic Anemia Market Aplastic anemia is a rare and serious non-cancerous condition marked by the autoimmune destruction of early blood-forming cells. The global incidence varies from 0.7 to 7.4 cases per million people annually, with higher rates observed in Asia compared to Europe and the United States . As per DelveInsight estimates, the total Incident population of aplastic anemia in the 7MM were around 2,500 cases in 2023. These cases are projected to increase during the forecast period. Based on severity, severe and very severe aplastic anemia patients contributed roughly 65%-80% of the total aplastic anemia patient population. HSCT remains the standard treatment for patients under 40 years old, while Immunosuppressive Therapies (IST) are the preferred approach for patients aged 40 and above. In terms of pharmacological treatments, Novartis' PROMACTA/REVOLADE is currently the leading revenue driver, followed by ISTs across the 7MM. According to Novartis, the primary revenue drivers for PROMACTA/REVOLADE are its use in patients with chronic immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA). PROMACTA was first approved in 2014 for use in relapsed/refractory SAA patients in the United States , with approvals following in Europe in 2015 and Japan in 2017. However, it was approved for use as a first-line treatment in combination with ISTs like ATG in the US in 2018, which expanded treatment options for first-line patients and contributed to increased revenue. The total aplastic anemia market size was found to be ~USD 270 million in 2023 in the 7MM, which is further expected to increase by 2034 due to several factors such as an increase in disease incidence in Asian countries, high patient uptake of PROMACTA (until expected patent expiry in 2025), approval of Teva Pharma's ALVAIZ in the US, and Kyowa Kirin's ROMIPLATE in Japan along with the expected launch of potential emerging therapies. Aplastic Anemia Pipeline Therapies and Key Companies REGN7257: Regeneron Pharmaceuticals OMISIRGE (omidubicel): Gamida Cell For a comprehensive view of the aplastic anemia market, check out the Aplastic Anemia Market Assessment Diamond-Blackfan Anemia Market Diamond-Blackfan anemia (DBA) is a rare genetic condition that primarily disrupts the bone marrow's ability to produce red blood cells, resulting in severe anemia. It is typically diagnosed during infancy or early childhood and presents with symptoms such as pale skin, fatigue, stunted growth, and physical abnormalities, which may include thumb deformities or heart defects in certain cases. In 2023, there were around 7,870 reported cases of Diamond-Blackfan anemia across the 7MM, with the United States accounting for about 70% of these cases. Within the US, approximately 46% of cases in 2023 were linked to mutations in the RPS19 gene , which plays a crucial role in ribosomal protein synthesis, contributing to its high prevalence in DBA. Diamond-Blackfan anemia is frequently associated with several congenital anomalies, with craniofacial and musculoskeletal defects being the most common. Craniofacial abnormalities were noted in over 30% of DBA patients across the 7MM in 2023. Although DBA has a significant impact on patient health, there are currently no FDA-approved treatments available for the condition. Treatment primarily involves corticosteroid combinations, chronic blood transfusions, iron chelation, and potentially curative hematopoietic stem cell transplantation (HSCT). In 2023, the total market size for Diamond-Blackfan anemia was USD 1.56 million in the 7MM and is projected to increase by 2034. The United States represents the largest share of the Diamond Blackfan Anemia market, accounting for a significant proportion compared to the EU4 ( Germany , Spain , Italy , France ), the United Kingdom , and Japan . In 2023, corticosteroids were the leading therapy for DBA, generating USD 1.1 million in revenue, making them the preferred first-line treatment option. Since there are no FDA-approved therapies available and no emerging companies are working to fill this gap, there is a significant opportunity for innovative treatments, like gene therapy, to make a meaningful difference and address the needs of DBA patients. For a deeper understanding of the Diamond-Blackfan anemia market landscape, explore the Diamond-Blackfan Anemia Market Outlook Trending Hematological Disorders Reports Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen) , Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda , among others. Sickle Cell Disease Market Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sickle cell disease companies, including Vertex Pharmaceuticals, CRISPR Therapeutics, Bluebird Bio, Global Blood Therapeutics, Pfizer , among others. Beta-Thalassemia Market Beta-Thalassemia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key beta-thalassemia companies, including Novartis, Merck, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, SILENCE Therapeutics , among others. Warm Autoimmune Hemolytic Anemia Market Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key wAIHA companies, including Zenas BioPharma, Sanofi, Johnson & Johnson, Novartis Pharmaceuticals, Incyte Corporation, Rigel Pharmaceuticals, Alpine Immune Sciences, Inc., Hutchison Medipharma Limited , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLPPeople with missing teeth may be able to grow new ones, say Japanese dentists testing a pioneering drug they hope will offer an alternative to dentures and implants. Unlike reptiles and fish, which usually replace their fangs on a regular basis, it is widely accepted that humans and most other mammals only grow two sets of teeth . But hidden underneath our gums are the dormant buds of a third generation, according to Katsu Takahashi, head of oral surgery at the Medical Research Institute Kitano Hospital in Osaka. His team launched clinical trials at Kyoto University Hospital in October, administering an experimental medicine to adult test subjects that they say has the potential to jumpstart the growth of these concealed teeth. It's a technology "completely new" to the world, Takahashi told AFP. Prosthetic treatments used for teeth lost to decay, disease or injury are often seen as costly and invasive. So "restoring natural teeth definitely has its advantages", said Takahashi, the project's lead researcher. Tests on mice and ferrets suggest that blocking a protein called USAG-1 can awaken the third set, and the researchers have published lab photographs of regrown animal teeth. In a study published last year, the team said their "antibody treatment in mice is effective for tooth regeneration and can be a breakthrough in treating tooth anomalies in humans". 'Only the beginning' For now, the dentists are prioritising the "dire" needs of patients with six or more permanent teeth missing from birth. The hereditary condition is said to affect around 0.1 percent of people, who can have severe trouble chewing, and in Japan often spend most of their adolescence wearing a face mask to hide the wide gaps in their mouth, Takahashi said. "This drug could be a game-changer for them," he added. The drug is therefore aimed primarily at children, and the researchers want to make it available as early as 2030. Angray Kang, a dentistry professor at Queen Mary University of London, only knows of one other team pursuing a similar objective of using antibodies to regrow or repair teeth. "I would say that the Takahashi group is leading the way," the immunotechnology expert, who is not connected to the Japanese research, told AFP. Takahashi's work is "exciting and worth pursuing", Kang said, in part because an antibody drug that targets a protein nearly identical to USAG-1 is already being used to treat osteoporosis. "The race to regenerate human teeth is not a short sprint, but by analogy a set of back-to-back consecutive ultra-marathons," he said. "This is only the beginning." Chengfei Zhang, a clinical professor in endodontics at the University of Hong Kong, said Takahashi's method is "innovative and holds potential". "The assertion that humans possess latent tooth buds capable of producing a third set of teeth is both revolutionary and controversial," he told AFP. He also cautioned that "outcomes observed in animals do not always directly translate to humans". The results of the animal experiments raise "questions about whether regenerated teeth could functionally and aesthetically replace missing teeth", Zhang added. 'Over the moon' A confident Takahashi argues that the location of a new tooth in a mouth can be controlled, if not pinpointed, by the drug injection site. And if it grows in the wrong place, it can be moved through orthodontics or transplantation, he said. No young patients with the congenital disorder are taking part in the first clinical trial, as the main objective is to test the drug's safety, rather than its effectiveness. So for now, the participants are healthy adults who have lost at least one existing tooth. And while tooth regeneration is not the express goal of the trial this time around, there is a slim chance that it could happen to subjects anyway, Takahashi said. If so, the researchers will have confirmed that the drug can be effective for those with acquired toothlessness—which would be a medical triumph. "I would be over the moon if that happens," Takahashi said. This could be particularly welcome news in Japan, which has the second-oldest population in the world. Health ministry data shows more than 90 percent of people aged 75 or older in Japan have at least one tooth missing. "Expectations are high that our technology can directly extend their healthy life expectancy," Takahashi said. © 2024 AFPTech stocks extended their rally to new heights on Monday, with the Nasdaq 100 index climbing over 1% to surpass 22,000 points, fueled by robust gains among key components in the index. Broadcom Inc. AVGO led the charge, soaring over 8% after receiving bullish price-target updates from analysts. The company's AI-driven growth potential gained further traction on Friday following its announcement of a collaboration with Apple Inc. AAPL to produce a cutting-edge AI chip. Tesla Inc. TSLA also rallied, jumping more than 5%, pushing its post-election gains to 85%, buoyed by positive analyst sentiment. Wedbush Securities described Tesla as a “game-changer” in AI and autonomous advancements under Trump's administration, adding to the bullish outlook. Among other indices, the Russell 2000 rose 1%, while the S&P 500 edged up 0.4%. The Dow Jones Industrial Average, however, dipped 0.2%, weighed down by losses in the energy and healthcare sectors. On the economic front, private-sector surveys showed a stronger-than-expected rebound in December activity. The services sector Purchasing Managers’ Index (PMI) surged to 58.5, the highest reading since October 2021. Meanwhile, the Composite PMI climbed to 56.6, its best level since April 2022, as robust growth in services offset continued weakness in manufacturing. Crypto-related assets gained fresh bullish momentum, driven by speculation about the U.S. government creating a Bitcoin Strategic Reserve fund. Meanwhile, MicroStrategy Inc. MSTR will be added to the Nasdaq 100 Index on Dec. 23, further boosting sentiment. Bitcoin BTC/USD reached $107,000, marking a year-to-date gain of 153%. MicroStrategy shares rose 5.8%, while other crypto-linked stocks, such as MARA Digital Holdings Inc. MARA , Riot Platforms Inc. RIOT , and Coinbase Inc. COIN , surged 11.1%, 9.2%, and 4.5%, respectively. Monday’s Performance In Major US Indices, ETFs Major Indices Price 1-day % Nasdaq 100 22,043.82 1.2% Russell 2000 2,369.39 1.0% S&P 500 6,076.94 0.4% Dow Jones 43,750.42 -0.2% According to Benzinga Pro data: The SPDR S&P 500 ETF Trust SPY rose 0.5% to $607.34. The SPDR Dow Jones Industrial Average DIA eased 0.2% to $438.86. The tech-heavy Invesco QQQ Trust Series QQQ rose 1.4% to $537.94. The iShares Russell 2000 ETF IWM rose 1% to $235.13. The Consumer Discretionary Select Sector SPDR Fund XLY outperformed, up by 1.2%; the Energy Select Sector SPDR Fund XLE lagged, down 1.8%. Monday’s Stock Movers Micron Technology Inc. MU rose 7.1%, reflecting bullish investor sentiment ahead of its earnings report on Wednesday after the close. Alphabet Inc. GOOGL rose by 4.7%, building up momentum after last week’s 8.7% surge following the announcement of the quantum computer launch. Shares of of natural gas companies fell amid prospects for less colder weather in the upcoming weeks. New Fortress Energy Inc. NFE led industry declines, down 7%. Read Next: Fed Poised To Cut Interest Rates By 0.25% This Week: Here’s Why Your Focus Should Shift To Other Signals Photo: Shutterstock © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Iraola expects 'dynamic' game against Seagulls - but is wary of the windBroadridge Financial Solutions Inc. stock outperforms competitors despite losses on the day'Favorite event': Veterans salute senior neighbors around Aiken County

FAAC shares N1.827trn revenue with federal, state, local governments in NovemberSDB bank has announced the appointment of Chitral De Silva to its Corporate Management team as the Deputy General Manager/Chief Business Officer. With a distinguished career spanning over four decades in the banking sector, De Silva brings a wealth of expertise and a proven track record of driving transformational growth. De Silva’s illustrious career began at Deutsche Bank, where he honed his skills in banking operations. He later held senior leadership roles at Seylan Bank, where he played a pivotal role in the organisation’s success. His areas of expertise include Branch Banking Operations, Development Banking, Recoveries, Remittances, and delivering strategic business outcomes. Beyond traditional banking, De Silva has showcased his adaptability and innovative mindset through his consultancy in Business Development with Emojot Inc., a Silicon Valley-based information technology company, focusing on digital transformation and customer-centric solutions. Throughout his career, De Silva has consistently delivered exceptional results, including expanding branch networks, enhancing profitability, and spearheading key strategic initiatives. His experience in implementing digital banking solutions, optimising operational efficiency, and fostering robust customer engagement positions him as a valuable asset to SDB bank. SDB bank remains committed to its vision of empowering communities through innovative financial solutions. The addition of De Silva to the Corporate Management team underscores the bank’s dedication to strengthening its leadership and delivering unparalleled value to its stakeholders.

Ancient engraved amulet could ‘turn back history’ of Christianity, experts claimHawaii Bowl: USF vs. San Jose State odds, picks and predictions

Estee Lauder Cos. Cl A stock outperforms competitors on strong trading dayFACT FOCUS: Inspector general’s Jan. 6 report misrepresented as proof of FBI setupSome Educated Guesses About Trump’s Second Term

There’s a boom coming. Bitcoin has arrived, and its price is setting records. Artificial Intelligence is hot. And the American people just elected a president with a deregulatory mindset. All the ingredients are there. If everything is handled right, America will soon embark on a period of extended wealth creation rarely seen in modern history. For that to occur, a few things must happen, starting with the government staying largely out of the way. That’s hard to do since people rely on government to keep the currency and other mediums of exchange stable. It’s also supposed to root out and protect against fraudsters who take advantage of the hype surrounding any innovative technology to prey on unsuspecting, naïve investors looking to, as the saying goes, “get rich quick.” None of that has to be tossed overboard in pursuit of the newest “new economy.” As we move forward with the integration of crypto technology into the global financial system and overlay AI onto the manufacturing sector, Caveat Emptor — let the buyer beware — is still a sound strategy for everyone. The better the industry educates the American public about what digital tokens are, how to tell the good from the bad, and how they can be used to transform commerce, the more quickly it will be adopted widely. The same goes for AI, which, up to now, is still talked about as though it were part of a science-fiction future where computers dominate humankind. What people don’t know or are choosing to ignore is that AI is already being used — to significant effect — in health care, energy and manufacturing, leading to lower costs, increased efficiency and driving breakthroughs that benefit us all. The Mayo Clinic says that AI is already improving the quality of preventive screenings, diagnoses and treatments, particularly for cancer patients who are experiencing improved outcomes. The power behind Bitcoin is also making health care better, at least IBM thinks it is. The company has used blockchain, the technology that makes cryptocurrency viable as a transferable store of value, to make health data systems for the Centers for Disease Control better and safer. Accenture and Shell have partnered to use crypto technology to develop an airline booking system for American Express where business travelers can choose to reduce their carbon footprint by quickly matching them with flights that use cleaner fuel. There are groups out there, like the National Cryptocurrency Association, that are working to share information and best practices and educate consumers about the benefits of broader adoption of blockchain. They’re also working to combat misinformation and address the general lack of understanding at the end-user level regarding crypto. Blockchain seems to have a leg up on AI in this regard, but that’s perhaps because it’s been around longer. Nevertheless, the rules of the road are still being written. Gary Gensler, the crypto skeptic who served as chairman of the United States Securities and Exchange Commission under President Joe Biden, announced recently he’d be stepping down at the end of the current administration. Trump can now replace him with someone friendly to crypto who can promulgate a set of rules that will allow America to close the gap its regulatory inaction has created with nations like China, which are much farther down the road on digital finance. There is growing recognition that a similar effort needs to be made with AI so that the public better understands how it works. The American Association of Retired Persons is one group that recently launched a major initiative, but more needs to be done. Groups like it and the NCA can and should take the lead in educating the public about these technologies, how they work, and why they are worth paying attention to. Modern technologies are for everyone, not a select few. Increasing awareness and education will help us better leverage these technologies from both a practical and policy perspective and will open the door for safe and beneficial mass adoption. We need to bring the public along instead of frightening them.Match Awards from FC Bayern’s strong-ish 3-0 win over FC Augsburg

A lawyer who is currently helping Robert F. Kennedy Jr. pick federal health officials once petitioned the Food and Drug Administration to revoke its approval for multiple critical childhood vaccines, including the polio vaccine. Aaron Siri, managing partner at Siri & Glimstad LLP, has a history of challenging the FDA to pause or completely withdraw various vaccines – a move which raises concerns given Kennedy’s historic anti-vaccine rhetoric. In 2022, Siri asked the FDA Commissioner, on behalf of the Informed Consent Action Network, to cease its use of the polio vaccine in infants and toddlers. The petition claimed the vaccine was not properly tested to ensure it was safe, despite its decade-long use protecting millions of children from contracting the disease which can cause paralysis. He filed a similar petition to withdraw a hepatitis B vaccine in children in 2020. In 2021, Siri asked the FDA, again on behalf of the Informed Consent Action Network, to pause its use of six childhood vaccines that protect against tetanus, diphtheria, pertussis and hepatitis A until they disclosed information about aluminum in them. It appears Siri already possesses a strong influence on Kennedy because he is helping him question and choose potential leaders for top federal health jobs. One person familiar with conversations told the New York Times , that the two have questioned potential candidates about their views on vaccines. The revelation, first reported by the New York Times , is alarming due to Kennedy’s status as the Health and Human Services secretary nominee. Kennedy already faces an uphill battle to get his nomination approved by the Senate because he has made anti-vaccine statements in the past and elevated health-related conspiracy theories. Many, including 75 Nobel Prize winners, have urged senators not to confirm him due to his criticisms of mainstream medicine. In the past, Kennedy has linked vaccines to autism – a debunked theory with no scientific or medical proof. He’s claimed that “no vaccine” is safe and effective – which is also false. He has also attributed mental health issues, like those that drive people to commit mass shootings, to pharmaceuticals. Both antidepressant use and mass shooting occurrences have increased in the last several decades, the scientific community has found “no biological plausibility” to back a link between the two, according to Ragy Girgis, an associate professor of clinical psychiatry at Columbia University, per the New York Times . Vaccines are proven to be a crucial and effective way to prevent the spread of deadly diseases. Kennedy has assured people he will not “take away” vaccines, as does Siri, and claims he is not anti-vax. But it is unclear what he will do with vaccines should he be confirmed. A spokesperson for Kennedy told the New York Times , “Mr. Kennedy has long said that he wants transparency in vaccines and to give people choice.”Burt, the huge Australian crocodile who had a cameo in ‘Crocodile Dundee,’ dies at 90More than 60 high school students in Los Angeles County learned to use technology to make business plans in an after-school program, which ended last week with the Young Innovators Accelerator Pitch Competition. The after-school program took place at six across Los Angeles County. The centers are run by nonprofits in under-resourced neighborhoods with funding from the Best Buy Foundation, the Annenberg Foundation and the Greater Los Angeles Education Foundation (GLAEF), the philanthropic arm of the Los Angeles County Office of Education. The Teen Tech Centers aim to give area students a chance to play with the latest technology — and gain job skills in the process, according to Sam Gelinas, vice president of programs, strategy and development at GLAEF. The Young Innovators Accelerator Pitch Competition, now in its second year, furthers the focus on job skills, he said. “The process of developing a budget, developing all the assets, all of that stuff, they’re building some of those soft business skills, and then also some of the tech skills like actually designing a deck and those kinds of things,” Gelinas said. Curriculum and training for the program were provided by the Los Angeles Economic Equity Accelerator and Fellowship, a nonprofit based out of California State University, Los Angeles, Gelinas said. “The trainers were young and dynamic and sort of met students where they were and walked them through the elements of entrepreneurship,” he said. On top of learning to use technology to build a business plan, many of the students came up with services that center on tech. For example, the winning idea at last week’s competition was an artificial intelligence-driven ed-tech tool, pitched by 14-year-old Gabriel Cardenas. Called ByteAi, the tool would use AI to transform complex classroom subjects into “bite-sized” lessons, without telling students any answers, according to Cardenas, a freshman at the California Academy of Math and Science in Long Beach. “My teacher would give me an assignment, and it was really hard for me to completely understand what I really needed to learn,” Cardenas said. “With this, you could ask the AI to break it down and make it more understandable, and it would give you key highlights, quizzes and games.” Among the six business plans that made it to the competition last week, three others were also based on tech: a peer-to-peer mental health social app, an interchangeable lens camera with smart connectivity and auto focus, and an app to help people find healthy food options. Cardenas took home first place and $1,400 for ByteAi, while Tristen Trudgeon won second place and $1,000 for BeSeen, the mental health app. Third place and $600 went to a team of seven students for their pitch to create a community market where homeless people could work. Three other semi-finalists each received $150. Gelinas said he hopes the Young Innovators Accelerator Pitch Competition will continue to be an annual event. Funding for the program came from GLAEF, the Best Buy Foundation, Annenberg Tech and the Calley Foundation, he said.

Waltham, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a supplier of Additive Manufacturing solutions, today shared its response to a December 20, 2024 lawsuit filed by Desktop Metal, Inc. (NYSE: DM) (“Desktop Metal”) against the Company in the Delaware Court of Chancery alleging Nano Dimension has failed to use its reasonable best efforts to obtain regulatory approval in connection with the merger agreement between the parties dated July 2, 2024 (the “Merger Agreement”). The Company believes the lawsuit is without merit and inconsistent with the terms of the Merger Agreement, particularly with respect to the Company’s right to work through the review process that is under way with the Committee on Foreign Investment in the United States ("CFIUS"). The Company believes the lawsuit is nothing more than an effort by Desktop Metal to prevent the Company from exercising its rights under the Merger Agreement and to impose deadlines and obligations that are inconsistent with that agreement. The Company intends to vigorously defend itself and preserve its rights under the Merger Agreement. About Nano Dimension Ltd. Nano Dimension (Nasdaq: NNDM) offers a variety of Digital Manufacturing technologies serving customers across vertical target markets such as aerospace and defense, advanced automotive, high-tech industrial, specialty medical technology, and R&D and academia. With its suite of digital manufacturing technologies, Nano Dimension is enabling its customers with prototyping and high-mix-low-volume production, along with IP security, design-for-manufacturing capabilities, and more sustainable means of fabrication. For more information, please visit https://www.nano-di.com/ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For example, Nano is using forward-looking statements in this press release when it discusses (i) its beliefs regarding the merits of the lawsuit filed by Desktop Metal, (ii) its beliefs regarding the lawsuit with respect to Nano’s rights under the Merger Agreement and (iii) its intention to vigorously defend itself against the lawsuit and preserve its rights under the Merger Agreement. Such forward-looking statements include statements regarding Nano’s future intentions, strategic plan, events or developments that Nano intends, expects, projects, believes or anticipates will or may occur in the future. Such statements are based on management’s beliefs and assumptions made based on information currently available to management. When used in this communication, the words “outlook,” “guidance,” “expects,” “believes,” “anticipates,” “should,” “estimates,” “may,” “will,” “intends,” “projects,” “could,” “would,” “estimate,” “potential,” “continue,” “plan,” “target,” or the negative of these words or similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results and performance to be materially different from those expressed or implied in the forward-looking statements. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. Because such statements deal with future events and are based on the current expectations of Nano, they are subject to various risks and uncertainties. Factors and risks that may cause Nano’s actual results or performance to be materially different from those expressed or implied in the forward-looking statements include, but are not limited to, (i) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction; (ii) the satisfaction of the closing conditions of the proposed transaction; and (iii) other risks related to the completion of the proposed transaction and actions related thereto. Except as otherwise required by law, Nano undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this communication. Nano is not responsible for the contents of third-party websites. Nano Dimension Contacts Investors: Julien Lederman, VP Corporate Development | ir@nano-di.com Media: Kal Goldberg / Bryan Locke / Kelsey Markovich | NanoDimension@fgsglobal.comThe Hollywood nostalgia machine has been spinning its wheels. But if there’s anyone who knows a thing or two about spinning wheels, it’s NASCAR driver Frankie Muniz, who’s just signed on to star in a limited run of four new episodes of Malcolm in the Middle , Disney+ announced today. Bryan Cranston and Jane Kaczmarek are also set to reprise their roles, with the original series’ creator Linwood Boomer returning as a writer and executive producer. The new batch of episodes will follow a middle-age Malcolm and his daughter getting dragged back into the family’s dysfunction at Hal and Lois’s 40th wedding-anniversary party. No premiere date has been set yet. There’s been some speculation as to whether the Wilkerson family would grace our screens again, with Muniz revealing in 2022 that Cranston had been working on a script . But the better question is, should they? Malcolm led the single-cam sitcom charge when it debuted nearly 25 years ago, and much of its humor and core pathos relied on a scrappy optimism that feels outdated in today’s political climate (not to mention, its series finale saw Malcolm set off on a trajectory toward becoming the people’s president — as opposed to, you know, another multimillionaire demagogue taking office ...). There’s also no word on if any of the other brothers will be appearing. Who will Malcolm be in the middle of? But maybe we needn’t be worried at all, and the years have given the show’s creators plenty of great ideas for material. For instance, a plotline about a cat flooding the family’s home could be comedy gold.

Xavier tries to get right vs. Morgan State before rivalry clashNEW YORK (AP) — The man accused of fatally shooting the CEO of UnitedHealthcare pleaded not guilty on Monday to state murder and terror charges while his attorney complained that comments coming from New York’s mayor would make it tough to receive a fair trial. Luigi Mangione, 26, was shackled and seated in a Manhattan court when he leaned over to a microphone to enter his plea. The Manhattan district attorney charged him last week with multiple counts of murder, including murder as an act of terrorism. Mangione's initial appearance in New York’s state trial court was preempted by federal prosecutors bringing their own charges over the shooting. The federal charges could carry the possibility of the death penalty, while the maximum sentence for the state charges is life in prison without parole. Prosecutors have said the two cases will proceed on parallel tracks, with the state charges expected to go to trial first. One of Mangione’s attorneys told a judge that government officials, including New York Mayor Eric Adams, have turned Mangione into a political pawn, robbing him of his rights as a defendant and tainting the jury pool. “I am very concerned about my client’s right to a fair trial,” said Karen Friedman Agnifilo. Adams and Police Commissioner Jessica Tisch stood among a throng of heavily armed officers last Thursday when Mangione was flown to a Manhattan heliport and escorted up a pier after being extradited from Pennsylvania. Friedman Agnifilo said police turned Mangione’s return to New York into a choreographed spectacle. “He was on display for everyone to see in the biggest stage perp walk I’ve ever seen in my career. It was absolutely unnecessary,” she said. In a statement, Adams spokesperson Kayla Mamelak Altus said: “Critics can say all they want, but showing up to support our law enforcement and sending the message to New Yorkers that violence and vitriol have no place in our city is who Mayor Eric Adams is to his core.” “The cold-blooded assassination of Brian Thompson — a father of two — and the terror it infused on the streets of New York City for days has since been sickeningly glorified, shining a spotlight on the darkest corners of the internet,” Mamelak Altus said. Friedman Agnifilo also accused federal and state prosecutors of advancing conflicting legal theories, calling their approach confusing and highly unusual. “He is being treated like a human ping pong ball between warring jurisdictions here,” she said Monday. State trial court Judge Gregory Carro said he has little control over what happens outside the courtroom, but can guarantee Mangione will receive a fair trial. Authorities say Mangione gunned down Thompson as he was walking to an investor conference in midtown Manhattan on the morning of Dec 4. Mangione was arrested in a Pennsylvania McDonald’s after a five-day search, carrying a gun that matched the one used in the shooting and a fake ID, police said. He also was carrying a notebook expressing hostility toward the health insurance industry and especially wealthy executives, according to federal prosecutors. At a news conference last week, Manhattan District Attorney Alvin Bragg said the application of the terrorism law reflected the severity of a “frightening, well-planned, targeted murder that was intended to cause shock and attention and intimidation.” “In its most basic terms, this was a killing that was intended to evoke terror,” he added. Mangione is being held in a Brooklyn federal jail alongside several other high-profile defendants, including Sean “Diddy” Combs and Sam Bankman-Fried. During his court appearance Monday, he smiled at times when talking with his attorneys and stretched his right hand after an officer removed his cuffs. Outside the courthouse, a few dozen supporters chanted, “Free Luigi,” over the blare of a trumpet. Natalie Monarrez, a 55-year-old Staten Island resident, said she joined the demonstration because she lost both her mother and her life savings as a result of denied insurance claims. “As extreme as it was, it jolted the conversation that we need to deal with this issue,” she said of the shooting. “Enough is enough, people are fed up.” An Ivy-league graduate from a prominent Maryland family, Mangione appeared to have cut himself off from family and friends in recent months. He posted frequently in online forums about his struggles with back pain. He was never a UnitedHealthcare client, according to the insurer. Thompson, a married father of two high-schoolers, had worked at the giant UnitedHealth Group for 20 years and became CEO of its insurance arm in 2021. The killing has prompted some to voice their resentment at U.S. health insurers, with Mangione serving as a stand-in for frustrations over coverage denials and hefty medical bills. It also has sent shockwaves through the corporate world, rattling executives who say they have received a spike in threats.CONCORD, N.H. (AP) — School district officials who punished two parents for wearing pink wristbands marked “XX” during a soccer game featuring a transgender player defended their decision Friday at a hearing on whether they can take similar action while they are being sued. Kyle Fellers and Anthony Foote were banned from school grounds after the September game by officials who viewed the wristbands as intimidation or harassment of a transgender player. They later sued the Bow school district, and while the no-trespass orders have since expired, a judge is deciding whether the plaintiffs should be allowed to wear the wristbands and carry signs at upcoming school events, including basketball games, swim meets and a music concert, while the case proceeds. Both men testified Thursday that they didn’t intend to harass or otherwise target a transgender player on the opposing team, and their attorneys have argued they did nothing more than silently express their support for reserving girls’ sports for those born female. But school officials testified Friday that they had reason to believe the men wouldn’t stop there. Superintendent Marcy Kelley and Bow High School Athletic Director Michael Desiletes described receiving strongly-worded emails from Foote in which he called himself a “real leader” who was prepared to take action and seeing his social media posts urging others to attend the game. In the days leading up to the game, another parent told school officials she overheard others talk about showing up to the game wearing dresses and heckling the transgender player. “When we suspect there’s some sort of threat ... we don’t wait for it to happen,” Kelley said, comparing it to the way school officials wouldn’t wait until a fight broke out between two students to intervene if they got wind of it beforehand. Kelley also pushed back on the idea that the plaintiffs were simply expressing support for their daughters and their teammates in general, noting that they chose the one game involving a transgender player to begin wearing the wristbands. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Iran said Friday it would launch a series of “new and advanced” centrifuges in response to a resolution adopted by the UN nuclear watchdog that censures Tehran for what the agency called lack of cooperation. The censure motion brought by Britain, France, Germany, and the United States at the 35-nation board of the International Atomic Energy Agency (IAEA) follows a similar one in June. The resolution — which China, Russia and Burkina Faso voted against — was carried with 19 votes in favour, 12 abstentions and Venezuela not participating, two diplomats told AFP. “The head of the Atomic Energy Organization of Iran issued an order to take effective measures, including launching a significant series of new and advanced centrifuges of various types,” a joint statement by the organisation and Iran’s foreign ministry said. Centrifuges are the machines that enrich uranium transformed into gas by rotating it at very high speed, increasing the proportion of fissile isotope material (U-235). “At the same time, technical and safeguards cooperation with the IAEA will continue, as in the past” and within the framework of agreements made by Iran, the joint Iranian statement added. Iran’s retaliatory measures “are reversible if this (Western) hostile action is withdrawn or negotiations are opened,” Tehran-based political analyst Hadi Mohammadi told AFP. The resolution comes with tensions running high over Iran’s atomic programme, with critics fearing that Tehran is attempting to develop a nuclear weapon — a claim the Islamic republic has repeatedly denied.By Clarissa-Jan Lim Days after Daniel Penny was acquitted in the chokehold death of Jordan Neely , he is set to attend an Army-Navy football game Saturday as a guest of Vice President-elect JD Vance. Vance said that Penny had accepted his invite to the game in a post on X on Friday morning. “Daniel’s a good guy, and New York’s mob district attorney tried to ruin his life for having a backbone,” Vance wrote. “I’m grateful he accepted my invitation and hope he’s able to have fun and appreciate how much his fellow citizens admire his courage.” Like others on the political right , Vance hailed Penny as a good Samaritan who helped his fellow citizens by confronting a potentially dangerous situation. Neely, a former Michael Jackson impersonator with a history of mental illness, died after Penny restrained him by the neck for an extended period of time during an encounter on the New York City subway in 2023. Penny argued that he meant to restrain Neely only until police arrived and did not intend to harm him. A New York City medical examiner ruled that Neely died from compression to his neck as a result of the chokehold. A jury cleared Penny of criminally negligent homicide in Neely’s death Monday after failing to come to an agreement on a charge of second-degree manslaughter , which a judge then dismissed. Penny’s ascension to folk hero status on the right is not unlike the support that Kyle Rittenhouse gained among conservatives after fatally shooting two people during a Black Lives Matter protest in Kenosha, Wisconsin, in 2020. Rittenhouse was acquitted of homicide charges in the case, and Donald Trump met with Rittenhouse afterward, praising him as “really a nice young man.” There are vast differences in the details of each case, but the lionization of Penny on the right coincides with the narrative about rising crime across the country, especially in urban areas like New York City. National data crime data , however, indicates the opposite . Clarissa-Jan Lim is a breaking/trending news blogger for MSNBC Digital. She was previously a senior reporter and editor at BuzzFeed News.

Scottish international Adams scores long-range stunner in Serie A win for TorinoFACT FOCUS: Inspector general’s Jan. 6 report misrepresented as proof of FBI setup